EUVIMEDEUVIMED entdecken
Crossref

Jie Geng Tang reverses cisplatin resistance through the Nrf2 pathway in lung cancer

Jing Zhao, Manting Hou, Kaixin Ding, Shixiong Li, Hui Li, Xili Zhang iD, Zhaofang Bai iD, Wenlong Liu iD

Journal of Pharmacy and Pharmacology · 2023

DOI: 10.1093/jpp/rgad018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Jing Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hunan University of Chinese Medicine, Changsha, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation of China, Scientific Research Fund of Hunan Provincial Education Department, Pharmaceutical Open Fund of Domestic First-class Disciplines (Cultivation) of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Jie Geng Tang (JGT) is an ancient traditional Chinese herbal decoction that exhibits various pharmacological activities, however, is poorly understood in the sensitivity of lung cancer to chemotherapy. Here, we explored the effect of JGT on sensitizing cisplatin (DDP)-resistant A549 cells (A549/DDP).

Methods

Cell viability was assessed using cell counting kit-8 assay. Flow cytometry was applied to detected cell apoptosis, mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) levels. Western blotting and qRT-PCR were performed to determine protein and mRNA levels. Key findings The results demonstrated that DDP co-treatment with JGT significantly increased the cytotoxicity of A549/DDP cells and exhibited efficacy in suppressing the migration and proliferation. The rate of apoptosis was increased by co-treatment with DDP and JGT, along with a higher rate of Bax/Bcl-2, and increased loss of MMP. Furthermore, the combination promoted ROS accumulation and increased γ-H2AX levels. Moreover, Nrf2 levels were suppressed in a dose- and time-dependent manner, Nrf2 stability was reduced following treatment with JGT. Notably, the combination induced inhibition of the Nrf2/ARE pathway at the mRNA and protein levels.

Conclusions

Collectively, these results indicate that co-treatment with JGT and DDP can be considered a combinational approach to treating DDP resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAntineoplastic AgentsHumansCisplatinNF-E2-Related Factor 2Reactive Oxygen SpeciesDrug Resistance, NeoplasmApoptosisCell ProliferationCell Line, Tumor

Stichwörter der Autor:innen

Jie Geng TangNrf2cisplatinlung cancer

Substanzen

CisplatinNF-E2-Related Factor 2Reactive Oxygen SpeciesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
  • Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • China Military Institute of Chinese Materia, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China.

ORCID-Profile: Xili Zhang, Zhaofang Bai, Wenlong Liu

Förderung

  • Hunan Provincial Natural Science Foundation of China
  • Scientific Research Fund of Hunan Provincial Education Department
  • Pharmaceutical Open Fund of Domestic First-class Disciplines (Cultivation) of Hunan Province

Zitieren

APA

Zhao, J., Hou, M., Ding, K., Li, S., Li, H., Zhang, X., Bai, Z., & Liu, W. (2023). Jie Geng Tang reverses cisplatin resistance through the Nrf2 pathway in lung cancer. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad018

Vancouver

Zhao J, Hou M, Ding K, Li S, Li H, Zhang X, et al. Jie Geng Tang reverses cisplatin resistance through the Nrf2 pathway in lung cancer. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad018

BibTeX
@article{Zhao2023,
  author = {Zhao, Jing and Hou, Manting and Ding, Kaixin and Li, Shixiong and Li, Hui and Zhang, Xili and Bai, Zhaofang and Liu, Wenlong},
  title = {Jie Geng Tang reverses cisplatin resistance through the Nrf2 pathway in lung cancer},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2023},
  doi = {10.1093/jpp/rgad018}
}
Kostenlos starten →